Vascular Biogenics Ltd.
NASDAQ:VBLT
Overview | Financials
Company Name | Vascular Biogenics Ltd. |
Symbol | VBLT |
Currency | USD |
Price | 0.156 |
Market Cap | 12,111,917 |
Dividend Yield | 0% |
52-week-range | 0.101 - 0.32 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Prof. Dror Harats M.D. |
Website | https://www.vblrx.com |
An error occurred while fetching data.
About Vascular Biogenics Ltd.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD